Literature DB >> 21480373

Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders.

Alisha E King1, Jim Mintz, Donald R Royall.   

Abstract

Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac (123) I-metaiodobenzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered (123) I-metaiodobenzylguanidine cardiac scintigraphy a "supportive" diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of (123) I-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of (123) I-metaiodobenzylguanidine uptake. (123) I-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. (123) I-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480373     DOI: 10.1002/mds.23659

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  37 in total

Review 1.  Diagnosis and differential diagnosis of MSA: boundary issues.

Authors:  Han-Joon Kim; Beom S Jeon; Kurt A Jellinger
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 2.  The spectrum of cognitive impairment in Lewy body diseases.

Authors:  Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases.

Authors:  Adrien Lebasnier; Guillaume Lamotte; Alain Manrique; Damien Peyronnet; Gerard Bouvard; Gilles Defer; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-28       Impact factor: 9.236

Review 4.  The clinical approach to autonomic failure in neurological disorders.

Authors:  Eduardo E Benarroch
Journal:  Nat Rev Neurol       Date:  2014-05-27       Impact factor: 42.937

Review 5.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

6.  Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease.

Authors:  Joong-Seok Kim; Yoon-Sang Oh; Kwang-Soo Lee; Yeong-In Kim; Dong-Won Yang; David S Goldstein
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

Review 7.  MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.

Authors:  Giorgio Treglia; Ernesto Cason; Antonella Stefanelli; Fabrizio Cocciolillo; Daniela Di Giuda; Giorgio Fagioli; Alessandro Giordano
Journal:  Clin Auton Res       Date:  2011-07-27       Impact factor: 4.435

8.  Myocardial MIBG scintigraphy in genetic Parkinson's disease as a model for Lewy body disorders.

Authors:  Iñigo Gabilondo; Verónica Llorens; Trinidad Rodriguez; Manuel Fernández; Tomas Pérez Concha; Marian Acera; Beatriz Tijero; Ane Murueta-Goyena; Rocío Del Pino; Jesús Cortés; Juan Carlos Gómez-Esteban
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-15       Impact factor: 9.236

Review 9.  Lewy body dementias.

Authors:  Zuzana Walker; Katherine L Possin; Bradley F Boeve; Dag Aarsland
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

Review 10.  Multiple system atrophy: pathogenic mechanisms and biomarkers.

Authors:  Kurt A Jellinger; Gregor K Wenning
Journal:  J Neural Transm (Vienna)       Date:  2016-04-20       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.